dynamics chronic myeloid leukaemia 
clinical success abl tyrosine kinase inhibitor imatinib chronic myeloid leukaemia cml serves model molecularly targeted therapy cancer- least two critical questions remain can imatinib eradicate leukaemic stem cells dynamics relapse due imatinib resistance caused mutations abl kinase domain precise understanding imatinib exerts therapeutic effect cml ability measure disease burden quantitative polymerase chain reaction provide opportunity develop mathematical approach find four-compartment model based known biology haematopoietic differentiation can explain kinetics molecular response imatinib patient data set successful therapy leads biphasic exponential decline leukaemic cells first slope per day represents turnover rate differentiated leukaemic cells second slope per day represents turnover rate leukaemic progenitors model suggests imatinib potent inhibitor production differentiated leukaemic cells deplete leukaemic stem cells calculate probability developing imatinib resistance mutations estimate time detection resistance model provides first quantitative insights vivo kinetics human cancer 
